Lantern Pharma Inc. (NASDAQ: LTRN) announced the presentation of clinical data from its ongoing Phase 1 trial of LP-284 at the 25th Annual Lymphoma, Leukemia & Myeloma (LL&M) Congress in New York City, October 14–17, 2025. The data highlighted a confirmed complete metabolic response in a 41-year-old patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL) who had exhausted multiple prior therapies, including R-CHOP chemotherapy, radiation, CD19 CAR-T cell therapy, and a CD3xCD20 bispecific antibody. The patient achieved a complete metabolic response with non-avid lesions after just two 28-day cycles of LP-284, administered intravenously on days 1, 8, and 15 of each cycle. At study entry, the patient had widespread multifocal bone lesions and rapid disease progression following all prior treatments. This outcome validates LP-284’s synthetic lethal mechanism, particularly in tumors with DNA damage repair deficiencies, and offers a potential therapeutic option for patients who have no effective treatments left after advanced immunotherapies. Panna Sharma, President and CEO of Lantern Pharma, called the result a pivotal moment in the drug’s development. She emphasized that the success in a patient who failed both CAR-T and bispecific therapy underscores the power of the company’s AI-driven RADR® platform in identifying novel, high-potential drug candidates at a fraction of the time and cost of traditional methods. The clinical data has generated strong interest from biopharmaceutical companies and clinical investigators, highlighting LP-284’s dual potential—both as a monotherapy for post-CAR-T and post-bispecific patients and as a combination partner with existing FDA-approved agents. Preclinical data show compelling synergy between LP-284 and rituximab, a widely used monoclonal antibody, suggesting enhanced efficacy when used together. The company is actively pursuing combination development opportunities, especially with bispecific antibodies and other approved therapies. DLBCL is the most common aggressive non-Hodgkin’s lymphoma, with about 200,000 new cases annually worldwide. Despite initial treatment success, relapse after advanced immunotherapies is common and associated with poor outcomes, with median survival often measured in months. An estimated 40,000 DLBCL patients in the US and EU progress after CAR-T therapy each year, and post-relapse treatment costs can exceed $500,000 per patient. LP-284’s off-the-shelf administration and demonstrated activity in this difficult-to-treat population could address both clinical and economic challenges. Lantern’s Phase 1a dose-escalation study (NCT06132503) continues to evaluate LP-284 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphomas and solid tumors. Early data show the drug is well tolerated, with primarily Grade 1–2 adverse events, and confirm the intended mechanism of action. The company also announced a recent European Patent Office allowance for LP-284’s composition of matter patent, extending global intellectual property protection through 2039. This, combined with clinical validation and growing partnership interest, supports accelerated development and potential strategic collaborations. Beyond oncology, Lantern is exploring LP-284’s potential in autoimmune and inflammatory conditions, where its selective B-cell depletion mechanism may offer therapeutic benefit. LP-284 is an investigational next-generation acylfulvene designed to exploit synthetic lethal interactions in cancer cells with DNA repair deficiencies. It primarily induces DNA lesions repaired by transcription-coupled nucleotide excision repair (TC-NER), with activity unaffected by TP53 mutations or antigen expression. Preclinical studies also show it can overcome resistance to ibrutinib and synergize with rituximab. The drug has received multiple FDA Orphan Drug Designations for mantle cell lymphoma and high-grade B-cell lymphomas. Lantern Pharma is an AI-driven biopharmaceutical company focused on transforming oncology drug discovery and development through its RADR® platform. The company continues to advance its pipeline and explore strategic partnerships to maximize the clinical and commercial potential of its drug candidates.